Liquid biopsy for diagnosing glioma tumors
Official title: The circTeloDIAG: a New Approach of Liquid Biopsy for the Diagnosis and Follow-up of Patients With Glioma Tumor
Run by Hospices Civils de Lyon · NCT04931732 · Data updated 2026-11-12
This study is testing if a simple blood test can help doctors find and understand glioma brain tumors better, making it easier to decide on the right treatment.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 90 Years |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | Hospices Civils de Lyon Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Bron) |
| Status | Recruiting |
| Started | November 4, 2021 |
| Main results expected | November 2026 |
| Study ends | November 2026 |
| Registry record updated | October 11, 2023 |
| Trial ID | NCT04931732 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adult patients with suspected newly or recurrent glioma (grade II or higher) who are eligible for surgical intervention.
✕Probably not a fit
Patients with suspected grade I tumors or those who refuse surgery may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on the use of liquid biopsy to detect glioma-specific oncogenic processes in peripheral blood, particularly through the analysis of circulating tumor DNA (ctDNA). Gliomas are the most common primary brain tumors, and their diagnosis is crucial for effective patient management. The study aims to refine glioma diagnosis by identifying molecular biomarkers that can aid in differentiating tumor grades and guiding treatment decisions. By utilizing liquid biopsy, the study seeks to establish a routine clinical testing method for gliomas, which currently lacks standardized approaches.
Why it matters
Potential benefit: If successful, this study could lead to more accurate and timely diagnoses of gliomas, improving treatment outcomes for patients.
How similar studies have gone: While liquid biopsy has shown promise in other cancers, its application for gliomas is still novel and untested in routine clinical settings.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patient * Obtainment of written informed consent * Suspected newly or recurrent glioma (grade ≥ II) on MRI * Patient eligible for surgery (biopsy or resection) * Decision of surgery (biopsy or resection) at neuro-oncology interdisciplinary tumor board Exclusion Criteria: * Rejection of consent by patient * Hemoglobin \< 7g/dl * Rejection of surgery by patient * Suspected grade I tumor on MRI
Where it's running
-
East Group Hospital, Hospices Civils de Lyon
Bron, France Recruiting
Study contacts
- Study coordinator: GARNIER Louis, Dr
- Email: louis.garnier@chu-lyon.fr
- Phone: +33 (0)4 72 68 13 59
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
YN003 injection in glioma patients
This phase 1 study tests whether YN003 injected IV is safe and tolerable for adults with recurrent or progressive glioma, and to explore how the drug behaves in the body and any early signs of activity.
-
Brain connectome project in adults with brain glioma undergoing surgery
This registry collects MRI data and clinical information from adults with glioma to see how brain networks relate to surgery and recovery.
-
Proton vs. Photon Radiation for Certain Grade 2–3 Gliomas
This study tests whether proton therapy can better preserve thinking and memory than photon therapy for adults with IDH-mutated grade 2–3 gliomas who need radiation.
-
Connectome-guided network planning for brain tumor surgery in eloquent areas
This study tests whether using patient-specific brain network maps from diffusion MRI can help surgeons plan and guide brain tumor removal in eloquent areas.
-
AI-powered analysis of brain MRI to help glioma care
Doctors will use AI to study existing MRI scans and patient data from adults with glioma to see if it can help with non-invasive diagnosis and treatment planning.
-
Safusidenib in IDH1-mutant glioma after vorasidenib progression
This trial tests safusidenib in people with IDH1-mutant glioma who progressed on vorasidenib and did not need immediate chemo or radiation.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.